Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Lymphoma

  Free Subscription


Articles published in Haematologica

Retrieve available abstracts of 242 articles:
HTML format



Single Articles


    July 2021
  1. LIN RJ, Owens CN, Drill E, Iannotta A, et al
    Prephase rituximab/prednisone therapy and aging-related, pro-inflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma
    Haematologica. 2021 Jul 22. doi: 10.3324/haematol.2021.278719.
    PubMed     Abstract available


  2. DODERO A, Guidetti A, Marino F, Tucci A, et al
    Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
    Haematologica. 2021 Jul 22. doi: 10.3324/haematol.2021.278638.
    PubMed     Abstract available


  3. STRATI P, De Vos S, Ruan J, Maddocks KJ, et al
    Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase 1b study.
    Haematologica. 2021 Jul 8. doi: 10.3324/haematol.2021.278654.
    PubMed     Abstract available


  4. RAM R, Grisariu S, Shargian-Alon L, Amit O, et al
    Toxicity and efficacy of chimeric antigen receptor T-cell in patients with diffuse large B cell lymphoma above the age of 70 years compare to younger patients - a matched control multi-center cohort study.
    Haematologica. 2021 Jul 8. doi: 10.3324/haematol.2021.278288.
    PubMed     Abstract available


  5. DUELL J, Maddocks KJ, Gonzalez-Barca E, Jurczak W, et al
    Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Haematologica. 2021 Jul 1. doi: 10.3324/haematol.2020.275958.
    PubMed     Abstract available


    June 2021
  6. BENKLI CY, Marcogliese AN, Agrusa JE, Adesina AM, et al
    Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients.
    Haematologica. 2021 Jun 24. doi: 10.3324/haematol.2021.278936.
    PubMed     Abstract available


  7. EVENS AM, Connors JM, Younes A, Ansell SM, et al
    Older patients (aged >/=60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
    Haematologica. 2021 Jun 24. doi: 10.3324/haematol.2021.278438.
    PubMed     Abstract available


  8. NAPOLI S, Cascione L, Rinaldi A, Spriano F, et al
    Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma.
    Haematologica. 2021 Jun 24. doi: 10.3324/haematol.2020.267096.
    PubMed     Abstract available


  9. RULE S, Barreto WG, Briones J, Carella AM, et al
    Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the Phase III MabCute study.
    Haematologica. 2021 Jun 17. doi: 10.3324/haematol.2020.274803.
    PubMed     Abstract available


  10. PECE R, Tavella S, Costa D, Varesano S, et al
    Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect.
    Haematologica. 2021 Jun 10. doi: 10.3324/haematol.2021.278469.
    PubMed     Abstract available


  11. SVOBODA J, Bair SM, Landsburg DJ, Dwivedy Nasta S, et al
    Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
    Haematologica. 2021;106:1705-1713.
    PubMed     Abstract available


    May 2021
  12. DLOUHY I, Armengol M, Recasens-Zorzo C, Ribeiro ML, et al
    Interleukin-1 receptor associated kinase 1/4 and bromodomain and extraterminal inhibitions converge on NF-kappaB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88(L265P) mutati
    Haematologica. 2021 May 13. doi: 10.3324/haematol.2020.278258.
    PubMed     Abstract available


  13. PILERI SA, Mazzara S, Derenzini E
    Plasmablastic lymphoma: one or more tumours?
    Haematologica. 2021 May 6. doi: 10.3324/haematol.2021.278841.
    PubMed    


  14. NIETO Y, Gruschkus S, Valdez BC, Jones RB, et al
    Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis.
    Haematologica. 2021 May 6. doi: 10.3324/haematol.2021.278311.
    PubMed     Abstract available


  15. RAMIS-ZALDIVAR JE, Gonzalez-Farre B, Nicolae A, Pack S, et al
    MAP-kinase and JAK-STAT pathways dysregulation in plasmablastic lymphoma.
    Haematologica. 2021 May 6. doi: 10.3324/haematol.2020.271957.
    PubMed     Abstract available


    April 2021
  16. STRAUS DJ
    Progress in understanding the biology of nodular lymphocyte predominant Hodgkin lymphoma.
    Haematologica. 2021 Apr 22. doi: 10.3324/haematol.2021.278785.
    PubMed     Abstract available


  17. PASCHOLD L, Willscher E, Bein J, Vornanen M, et al
    Evolutionary clonal trajectories in nodular lymphocyte predominant Hodgkin lymphoma with high transformation risk.
    Haematologica. 2021 Apr 22. doi: 10.3324/haematol.2021.278427.
    PubMed     Abstract available


  18. PICARDI M, Giordano C
    Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study."
    Haematologica. 2021;106:1226-1227.
    PubMed    


  19. BASTIDAS TORRES AN, Cats D, Out-Luiting JJ, Fanoni D, et al
    Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma.
    Haematologica. 2021 Apr 1. doi: 10.3324/haematol.2020.274506.
    PubMed     Abstract available


  20. MA MCJ, Tadros S, Bouska A, Heavican T, et al
    Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.
    Haematologica. 2021 Apr 1. doi: 10.3324/haematol.2020.274258.
    PubMed     Abstract available


    March 2021
  21. VAJAVAARA H, Ekeblad F, Holte H, Jorgensen J, et al
    Prognostic impact of soluble CD163 in patients with diffuse large Bcell lymphoma.
    Haematologica. 2021 Mar 25. doi: 10.3324/haematol.2020.278182.
    PubMed     Abstract available


  22. ABEYKOON JP, Hampel PJ, King RL, Wood AJ, et al
    The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma.
    Haematologica. 2021 Mar 4. doi: 10.3324/haematol.2020.278277.
    PubMed     Abstract available


    February 2021
  23. DOBSON R, Du PY, Raso-Barnett L, Yao WQ, et al
    Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis.
    Haematologica. 2021 Feb 11. doi: 10.3324/haematol.2020.265991.
    PubMed     Abstract available


  24. ROSCHEWSKI M
    Be mindful of the CNS in Burkitt lymphoma.
    Haematologica. 2021 Feb 4. doi: 10.3324/haematol.2020.278181.
    PubMed     Abstract available


  25. ZAYAC AS, Evens AM, Danilov A, Smith SD, et al
    Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multi-center cohort study.
    Haematologica. 2021 Feb 4. doi: 10.3324/haematol.2020.270876.
    PubMed     Abstract available


  26. ROSCHEWSKI M
    Central nervous system prophylaxis in diffuse large B-cell lymphoma: a race to the bottom.
    Haematologica. 2021;106:332-334.
    PubMed    


  27. BOBILLO S, Crespo M, Escudero L, Mayor R, et al
    Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas.
    Haematologica. 2021;106:513-521.
    PubMed     Abstract available


    January 2021
  28. KURTZ DM
    Bringing circulating tumor DNA to the clinic in Hodgkin lymphoma.
    Haematologica. 2021;106:5-6.
    PubMed    


    December 2020
  29. ROSSI C, Tosolini M, Gravelle P, Pericart S, et al
    Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma.
    Haematologica. 2020;Online ahead of print:0.
    PubMed     Abstract available


  30. RAMAN L, Van der Linden M, De Vriendt C, Van den Broeck B, et al
    Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential.
    Haematologica. 2020;Online ahead of print:0.
    PubMed     Abstract available


    November 2020
  31. TANG T, Martin P, Somasundaram N, Lim C, et al
    Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or naturalkiller/T-cell lymphoma.
    Haematologica. 2020;Online ahead of print:0.
    PubMed     Abstract available


  32. RIEKE DT, Keller U
    A CD205-directed antibody drug conjugate - lymphoma precision oncology or sophisticated chemotherapy?
    Haematologica. 2020;105:2504-2506.
    PubMed    


    October 2020
  33. ONG SY, Lim JQ, Grigoropoulos N, Laurensia Y, et al
    No association between ECSIT germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma.
    Haematologica. 2020;Online ahead of print.
    PubMed    


  34. STEPHENS DM, Boucher K, Kander E, Parikh SA, et al
    Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.
    Haematologica. 2020;Online ahead of print.
    PubMed     Abstract available


    September 2020
  35. YOUSSEF Y, Karkhanis V, Chan WK, Jeney F, et al
    Transducin beta-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma.
    Haematologica. 2020;Online ahead of print.
    PubMed     Abstract available


  36. MILLER PG, Sperling AS, Gibson CJ, Pozdnyakova O, et al
    A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade.
    Haematologica. 2020;Online ahead of print.
    PubMed    


  37. MAURA F, Dodero A, Carniti C, Bolli N, et al
    CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).
    Haematologica. 2020;Online ahead of print.
    PubMed     Abstract available


    August 2020
  38. VOGELSBERG A, Steinhilber J, Mankel B, Federmann B, et al
    Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype.
    Haematologica. 2020 Aug 27. pii: haematol.2020.254854.
    PubMed     Abstract available


  39. ISAEV K, Ennishi D, Hilton L, Skinnider B, et al
    Molecular Attributes Underlying Central Nervous System and Systemic Relapse in Diffuse Large B-cell Lymphoma.
    Haematologica. 2020 Aug 13. pii: haematol.2020.255950.
    PubMed    


  40. DERENZINI E, Mazzara S, Melle F, Motta G, et al
    A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma.
    Haematologica. 2020 Aug 13. pii: haematol.2019.236455.
    PubMed     Abstract available


  41. MATULIS SM, Boise LH
    BCL2 dependency in diffuse large B-cell lymphoma: it's a family affair.
    Haematologica. 2020;105:1993-1996.
    PubMed    


    July 2020
  42. STRATI P, Varma A, Adkins S, Nastoupil LJ, et al
    Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma.
    Haematologica. 2020 Jul 30. pii: haematol.2020.254045.
    PubMed     Abstract available


  43. THURNER L, Hartmann S, Bewarder M, Fadle N, et al
    Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B cell-type diffuse large B-cell lymphoma.
    Haematologica. 2020 Jul 16. pii: haematol.2019.241653.
    PubMed     Abstract available


  44. THORBALL CW, Oudot-Mellakh T, Ehsan N, Hammer C, et al
    Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma.
    Haematologica. 2020 Jul 16. pii: haematol.2020.247023.
    PubMed     Abstract available


    June 2020
  45. BERGER MD, Trelle S, Buchi AE, Jegerlehner S, et al
    Impact on survival through consolidation radiotherapy for diffuse large B-cell lymphoma: a comprehensive meta-analysis.
    Haematologica. 2020 Jun 18. pii: haematol.2020.249680.
    PubMed     Abstract available


  46. LEE J, Kim B, Lee H, Park H, et al
    Whole exome sequencing identifies mutational signatures of vitreoretinal lymphoma.
    Haematologica. 2020;105:e458-460.
    PubMed    


  47. MIYAZAKI K, Asano N, Yamada T, Miyawaki K, et al
    DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study.
    Haematologica. 2020;105:2308-2315.
    PubMed     Abstract available


  48. MINDERMAN M, Pals ST
    Towards genomic-based prognostication and precision therapy for diffuse large B-cell lymphoma.
    Haematologica. 2020;105:2194-2196.
    PubMed    


  49. PIRIS MA
    Peripheral T-cell lymphoma diagnosis: building a molecular tool.
    Haematologica. 2020;105:1472-1474.
    PubMed    


    May 2020
  50. TABANELLI V, Melle F, Motta G, Mazzara S, et al
    Evolutionary crossroads: morphological heterogeneity reflects divergent intra-clonal evolution in a case of high-grade B-cell lymphoma.
    Haematologica. 2020 May 28. pii: haematol.2020.249664.
    PubMed    


  51. OISHI N, Hundal T, Phillips JL, Dasari S, et al
    Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma.
    Haematologica. 2020 May 15. pii: haematol.2019.245860.
    PubMed     Abstract available


  52. WANG Z, Gong Q, Zhao Y, Xu H, et al
    Indolent EBV-positive T-cell lymphoproliferative disorder arising in a chronic pericardial hematoma: the T-cell counterpart of fibrin-associated diffuse large B-cell lymphoma?
    Haematologica. 2020 May 15. pii: haematol.2020.252007.
    PubMed    


  53. JACHIMOWICZ RD, Pieper L, Reinke S, Gontarewicz A, et al
    Analysis of the tumor microenvironment by whole-slide image analysis identifies low B cell content as a predictor of adverse outcome in advanced-stage classical Hodgkin lymphoma treated with BEACOPP.
    Haematologica. 2020 May 7. pii: haematol.2019.243287.
    PubMed     Abstract available


  54. MORSCHHAUSER F, Bouabdallah K, Stilgenbauer S, Thieblemont C, et al
    Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study.
    Haematologica. 2020 May 7. pii: haematol.2019.224535.
    PubMed    


  55. SEYMOUR JF, Marcus R, Davies A, Gallop-Evans E, et al
    Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
    Haematologica. 2020;105:1465.
    PubMed    


    April 2020
  56. LOGUE JM, Zucchetti E, Bachmeier CA, Krivenko GS, et al
    Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma.
    Haematologica. 2020 Apr 23. pii: haematol.2019.238634.
    PubMed     Abstract available


  57. LAROSE H, Prokoph N, Matthews JD, Schlederer M, et al
    Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target.
    Haematologica. 2020 Apr 23. pii: haematol.2019.238766.
    PubMed     Abstract available


  58. GERLACH MM, Stelling-Germani A, Wu CT, Newrzela S, et al
    SMAD1 promoter hypermethylation and lack of SMAD1 expression in Hodgkin lymphoma: a potential target for hypomethylating drug therapy.
    Haematologica. 2020 Apr 16. pii: haematol.2020.249276.
    PubMed    


  59. MOSER O, Zimmermann M, Meyer U, Klapper W, et al
    Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group.
    Haematologica. 2020 Apr 16. pii: haematol.2019.244780.
    PubMed     Abstract available


  60. GARBIN A, Lovisa F, Holmes AB, Damanti CC, et al
    miR-939 acts as tumor suppressor by modulating JUNB transcriptional activity in pediatric anaplastic large cell lymphoma.
    Haematologica. 2020 Apr 16. pii: haematol.2019.241307.
    PubMed    


  61. ARAF S, Korfi' K, Bewicke-Copley F, Wang J, et al
    Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma.
    Haematologica. 2020 Apr 9. pii: haematol.2019.242206.
    PubMed    


  62. GARCIA-REYERO J, Martinez Magunacelaya N, Gonzalez de Villambrosia S, Loghavi S, et al
    Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.
    Haematologica. 2020 Apr 9. pii: haematol.2020.251579.
    PubMed     Abstract available


  63. WANG L, Tang G, Medeiros LJ, Xu J, et al
    MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma.
    Haematologica. 2020 Apr 9. pii: haematol.2019.243071.
    PubMed     Abstract available


  64. KERSTEN MJ, Driessen J, Zijlstra JM, Plattel WJ, et al
    Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.
    Haematologica. 2020 Apr 9. pii: haematol.2019.243238.
    PubMed     Abstract available


  65. VAN DER MEULEN M, Bromberg JEC, Nijland M, Visser O, et al
    Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands.
    Haematologica. 2020 Apr 2. pii: haematol.2020.247536.
    PubMed    


    March 2020
  66. SUZUKI T, Fukuhara S, Nomoto J, Yamashita S, et al
    Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors.
    Haematologica. 2020 Mar 26. pii: haematol.2019.235598.
    PubMed    


  67. MONTESINOS-RONGEN M, Terrao M, May C, Marcus K, et al
    The process of somatic hypermutation increases polyreactivity for central nervous system antigens in primary central nervous system lymphoma.
    Haematologica. 2020 Mar 19. pii: haematol.2019.242701.
    PubMed     Abstract available


  68. WANG Y, Tschautscher MA, Rabe KG, Call TG, et al
    Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.
    Haematologica. 2020;105:765-773.
    PubMed     Abstract available


    February 2020
  69. SPARANO JA, Lee JY, Kaplan LD, Ramos JC, et al
    Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV- associated, B-cell non-Hodgkin's lymphoma.
    Haematologica. 2020 Feb 27. pii: haematol.2019.243386.
    PubMed     Abstract available


  70. CAMUS V, Viennot M, Lequesne J, Viailly PJ, et al
    Targeted genotyping of circulating tumor DNA for classical Hodgkin Lymphoma monitoring: a prospective study.
    Haematologica. 2020 Feb 20. pii: haematol.2019.237719.
    PubMed     Abstract available


  71. LIN RJ, Lobaugh SM, Pennisi M, Chan HT, et al
    Impact and safety of chimeric antigen receptor T cell therapy in older, vulnerable patients with relapsed/refractory large b-cell lymphoma.
    Haematologica. 2020 Feb 20. pii: haematol.2019.243246.
    PubMed    


  72. AUTIO M, Leivonen SK, Bruck O, Mustjoki S, et al
    Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma.
    Haematologica. 2020 Feb 20. pii: haematol.2019.243626.
    PubMed     Abstract available


  73. NAKAHATA S, Syahrul C, Nakatake A, Sakamoto K, et al
    Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma.
    Haematologica. 2020 Feb 13. pii: haematol.2019.234096.
    PubMed     Abstract available


  74. ZIEPERT M, Lazzi S, Santi R, Vergoni F, et al
    A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients.
    Haematologica. 2020 Feb 13. pii: haematol.2019.235556.
    PubMed    


  75. MANSON G, Brice P, Herbaux C, Bouabdallah K, et al
    Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation.
    Haematologica. 2020 Feb 13. pii: haematol.2019.242529.
    PubMed    


  76. STEFONI V, Marangon M, Re A, Lleshi A, et al
    Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS.
    Haematologica. 2020 Feb 13. pii: haematol.2019.243170.
    PubMed    


  77. VITTORIO STEFONI, Miriam Marangon, Alessandro Re, Arben Lleshi, et al
    Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS.
    Haematologica. 2020;105:e512.
    PubMed    


  78. MARITA ZIEPERT, Stefano Lazzi, Raffaella Santi, Federica Vergoni, et al
    A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients.
    Haematologica. 2020;105:2667-2670.
    PubMed    


  79. GUILLAUME MANSON, Pauline Brice, Charles Herbaux, Kamal Bouabdallah, et al
    Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation.
    Haematologica. 2020;105:2664-2666.
    PubMed    


  80. SARKAR A, Stellrecht CM, Vangapandu HV, Ayres M, et al
    Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma.
    Haematologica. 2020 Feb 6. pii: haematol.2019.234385.
    PubMed     Abstract available


  81. TOPP MS, Duell J, Abajo Guijarro AM, Odin M, et al
    Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma.
    Haematologica. 2020 Feb 6. pii: haematol.2019.233189.
    PubMed    


    January 2020
  82. LEE J, Kim B, Lee H, Park H, et al
    Whole exome sequencing identifies mutational signatures of vitreoretinal lymphoma.
    Haematologica. 2020 Jan 9. pii: haematol.2019.233783.
    PubMed    


  83. GAUDIO E, Tarantelli C, Spriano F, Guidetti F, et al
    Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models.
    Haematologica. 2020 Jan 9. pii: haematol.2019.227215.
    PubMed     Abstract available


  84. LEE S, Fujita K, Negoro E, Morishita T, et al
    Impact of relative dose intensity of standard regimens on survival in elderly patients aged 80 years and older with diffuse large B cell lymphoma.
    Haematologica. 2020 Jan 9. pii: haematol.2019.234435.
    PubMed    


  85. EUGENIO GAUDIO, Chiara Tarantelli, Filippo Spriano, Francesca Guidetti, et al
    Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models.
    Haematologica. 2020;105:2584-2591.
    PubMed     Abstract available


  86. CONCONI A, Thieblemont C, Cascione L, Torri V, et al
    Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment.
    Haematologica. 2020 Jan 2. pii: haematol.2019.237990.
    PubMed     Abstract available


  87. ANNARITA CONCONI, Catherine Thieblemont, Luciano Cascione, Valter Torri, et al
    Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment.
    Haematologica. 2020;105:2592-2597.
    PubMed     Abstract available


  88. LAFFON E, Marthan R
    Prognostic value of (18)F-FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project.
    Haematologica. 2020;105:e41.
    PubMed    


  89. BAILLY C, Carlier T, Kraeber-Bodere F, Le Gouill S, et al
    Reply to E. Laffon et al.
    Haematologica. 2020;105:e42.
    PubMed    


  90. STRATI P, Nastoupil LJ, Davis RE, Fayad LE, et al
    A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas.
    Haematologica. 2020;105:e26-e28.
    PubMed    


    December 2019
  91. CHAMULEAU MED, Burggraaff CN, Nijland M, Bakunina K, et al
    Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.
    Haematologica. 2019 Dec 19. pii: haematol.2019.238162.
    PubMed     Abstract available


    November 2019
  92. LIU Y, Rao J, Li J, Wen Q, et al
    Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma: a multiple center prospective study in China.
    Haematologica. 2019 Nov 28. pii: haematol.2019.226985.
    PubMed     Abstract available


  93. FUSTER C, Martin-Garcia D, Balague O, Navarro A, et al
    Cryptic insertions of the immunoglobulin light chain enhancer region near CCND1 in t(11;14)-negative mantle cell lymphoma.
    Haematologica. 2019 Nov 21. pii: haematol.2019.237073.
    PubMed    


  94. BOLEN CR, Klanova M, Trneny M, Sehn LH, et al
    Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study.
    Haematologica. 2019 Nov 14. pii: haematol.2019.227892.
    PubMed     Abstract available


  95. TSAI HJ, Tai JJ, Chen LT, Wu MS, et al
    A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue.
    Haematologica. 2019 Nov 14. pii: haematol.2019.228775.
    PubMed    


  96. KATAGIRI S, Makishima H, Azuma K, Nannya Y, et al
    Predisposed genomic instability in pre-treatment bone marrow evolves to therapy-related myeloid neoplasms in malignant lymphoma.
    Haematologica. 2019 Nov 7. pii: haematol.2019.229856.
    PubMed    


  97. BRUNA R, Benedetti F, Boccomini C, Patti C, et al
    Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial.
    Haematologica. 2019;104:2241-2248.
    PubMed     Abstract available


    October 2019
  98. DAMM-WELK C, Kutscher N, Zimmermann M, Attarbaschi A, et al
    Quantification of minimal disseminated disease by quantitative PCR and digital PCR for NPM-ALK as prognostic factor in children with anaplastic large cell lymphoma.
    Haematologica. 2019 Oct 24. pii: haematol.2019.232314.
    PubMed     Abstract available


  99. MIYAZAKI K, Asano N, Yamada T, Miyawaki K, et al
    DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study.
    Haematologica. 2019 Oct 24. pii: haematol.2019.231076.
    PubMed     Abstract available


  100. SMITH VM, Dietz A, Henz K, Bruecher D, et al
    Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma.
    Haematologica. 2019 Oct 10. pii: haematol.2019.220525.
    PubMed     Abstract available


  101. STRATI P, Ahmed MAA, Fowler N, Nastoupil LJ, et al
    Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma.
    Haematologica. 2019 Oct 10. pii: haematol.2019.230649.
    PubMed     Abstract available


  102. RECORD J, Sendel A, Kritikou JS, Kuznetsov NV, et al
    An intronic deletion in megakaryoblastic leukemia 1 is associated with hyperproliferation of B cells in triplets with Hodgkin lymphoma.
    Haematologica. 2019 Oct 3. pii: haematol.2019.216317.
    PubMed     Abstract available


    September 2019
  103. FERRERO S, Rossi D, Rinaldi A, Bruscaggin A, et al
    KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
    Haematologica. 2019 Sep 19. pii: haematol.2018.214056.
    PubMed     Abstract available


  104. TOWNSEND W, Pasikowska M, Yallop D, Phillips EH, et al
    The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T-cells.
    Haematologica. 2019 Sep 19. pii: haematol.2019.220160.
    PubMed     Abstract available


  105. DRIEUX F, Ruminy P, Abdel-Sater A, Lemonnier F, et al
    Defining the signatures of peripheral T-cell lymphoma, with a targeted 20-markers gene expression profiling assay (RT-MLPA).
    Haematologica. 2019 Sep 5. pii: haematol.2019.226647.
    PubMed     Abstract available


  106. EYRE TA, Djebbari F, Kirkwood AA, Collins GP, et al
    A systematic review of the efficacy of CNS prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era.
    Haematologica. 2019 Sep 5. pii: haematol.2019.229948.
    PubMed     Abstract available


    August 2019
  107. TEDESCHI A, Greil R, Demirkan F, Robak T, et al
    A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Haematologica. 2019 Aug 14. pii: haematol.2019.223743.
    PubMed    


  108. LI Z, Song Y, Zhang Y, Li C, et al
    Genomic and outcome analysis of adult T-cell lymphoblastic lymphoma.
    Haematologica. 2019 Aug 14. pii: haematol.2019.220863.
    PubMed    


  109. MIKA T, Ladigan S, Baraniskin A, Vangala D, et al
    Allogeneic hematopoietic stem cell transplantation for primary central nervous system lymphoma.
    Haematologica. 2019 Aug 8. pii: haematol.2019.227199.
    PubMed    


  110. TANAKA J, Tanaka N, Wang YH, Mistuhashi K, et al
    Phase I study of cellular therapy using ex vivo expanded NK cell from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients.
    Haematologica. 2019 Aug 8. pii: haematol.2019.226696.
    PubMed    


  111. SCHIEPPATI F, Balzarini P, Fisogni S, Re A, et al
    An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit of intensified treatment regimens.
    Haematologica. 2019 Aug 8. pii: haematol.2019.223891.
    PubMed     Abstract available


  112. NANN D, Bonzheim I, Muller I, Mankel B, et al
    Clonally related duodenal-type follicular lymphoma and in situ follicular neoplasia.
    Haematologica. 2019 Aug 1. pii: haematol.2019.226142.
    PubMed    


  113. BAILLY C, Carlier T, Berriolo-Riedinger A, Casasnovas O, et al
    Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project.
    Haematologica. 2019 Aug 1. pii: haematol.2019.223016.
    PubMed    


    July 2019
  114. FEDERMANN B, Frauenfeld L, Pertsch H, Borgmann V, et al
    Highly sensitive and specific in situ hybridization assay for quantification of SOX11 mRNA in mantle cell lymphoma reveals association of TP53 mutations with negative and low SOX11 expression.
    Haematologica. 2019 Jul 11. pii: haematol.2019.219543.
    PubMed     Abstract available


  115. ANDO M, Ando J, Yamazaki S, Ishii M, et al
    Long-term eradication of extranodal NK/T cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells in vivo.
    Haematologica. 2019 Jul 11. pii: haematol.2019.223511.
    PubMed     Abstract available


  116. VIDAL-CRESPO A, Matas-Cespedes A, Rodriguez V, Rossi C, et al
    Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.
    Haematologica. 2019 Jul 11. pii: haematol.2018.211904.
    PubMed     Abstract available


  117. XIE S, Wei F, Sun YM, Gao YL, et al
    EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma.
    Haematologica. 2019 Jul 9. pii: haematol.2019.222935.
    PubMed     Abstract available


    June 2019
  118. FALGAS A, Pallares V, Unzueta U, Cespedes MV, et al
    A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.
    Haematologica. 2019 Jun 27. pii: haematol.2018.211490.
    PubMed     Abstract available


  119. MARTIN-CORTAZAR C, Chiodo Y, Jimenez-P R, Bernabe M, et al
    CDCA7 finely tunes cytoskeleton dynamics to promote lymphoma migration and invasion.
    Haematologica. 2019 Jun 20. pii: haematol.2018.215459.
    PubMed     Abstract available


  120. NOWAKOWSKI GS, Chiappella A, Witzig TE, Scott DW, et al
    Variable global distribution of cell-of-origin from the ROBUST phase 3 study in diffuse large B-cell lymphoma.
    Haematologica. 2019 Jun 20. pii: haematol.2019.220475.
    PubMed    


  121. HU T, Chong Y, Lu S, McGuinness M, et al
    RAC1/2 activation promotes FGFR1 driven leukemogenesis in stem cell leukemia/lymphoma syndrome.
    Haematologica. 2019 Jun 20. pii: haematol.2018.208058.
    PubMed    


  122. FLINSENBERG TWH, Tromedjo CC, Hu N, Liu Y, et al
    Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK cell effector function in patients with mantle cell lymphoma.
    Haematologica. 2019 Jun 6. pii: haematol.2019.220590.
    PubMed    


  123. MARSCHALEK R
    Another piece of the puzzle added to understand t(4;11) leukemia better.
    Haematologica. 2019;104:1098-1100.
    PubMed    


    May 2019
  124. VERMAAT JS, Somers SF, de Wreede LC, Kraan W, et al
    MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavourable prognosis.
    Haematologica. 2019 May 23. pii: haematol.2018.214122.
    PubMed     Abstract available


  125. MAURER B, Nivarthi H, Wingelhofer B, Pham HTT, et al
    High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.
    Haematologica. 2019 May 23. pii: haematol.2019.216986.
    PubMed     Abstract available


  126. YUAN CT, Huang TC, Chuang CC, Chuang YK, et al
    Clonal sequence tracking reveals TET2-mutated extranodal NK/T-cell lymphoma disseminated independent of EB virus.
    Haematologica. 2019 May 16. pii: haematol.2018.215327.
    PubMed    


  127. WAGENER R, Bens S, Toprak UH, Seufert J, et al
    Cryptic insertion of MYC exons 2 and 3 into the IGH locus detected by whole genome sequencing in a case of MYC-negative Burkitt lymphoma.
    Haematologica. 2019 May 9. pii: haematol.2018.208140.
    PubMed    


  128. LIANG JH, Wang L, Zhu HY, Qian J, et al
    Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin's lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase 2 trial.
    Haematologica. 2019 May 9. pii: haematol.2019.220301.
    PubMed    


  129. PHILLIPS AA
    Response to the comment: "Identifying potential factors of variable response to mogamulizumab in adult T-cell leukemia/lymphoma between Japanese and other populations".
    Haematologica. 2019;104:e228.
    PubMed    


  130. JANAKIRAM M, Miljkovic MD
    Identifying potential factors of variable response to mogamulizumab in adult T-cell leukemia/lymphoma between Japanese and other populations.
    Haematologica. 2019;104:e227.
    PubMed    


  131. JOHNSON W, Mishra A, Binder A, Gru A, et al
    Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all four one or none for all?
    Haematologica. 2019;104:864-867.
    PubMed    


    April 2019
  132. CASCIONE L, Rinaldi A, Bruscaggin A, Tarantelli C, et al
    Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses.
    Haematologica. 2019 Apr 24. pii: haematol.2018.214957.
    PubMed    


  133. SIBON D, Nguyen DP, Schmitz N, Suzuki R, et al
    ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients.
    Haematologica. 2019 Apr 19. pii: haematol.2018.213512.
    PubMed    


  134. COOK LBM, Demontis MA, Sagawe S, Witkover A, et al
    Molecular remissions are observed in chronic adult T cell leukemia/lymphoma in patients treated with mogamulizumab.
    Haematologica. 2019 Apr 19. pii: haematol.2019.219253.
    PubMed    


  135. BELLEI M, Federico M
    The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective International T-Cell Project.
    Haematologica. 2019;104:e178.
    PubMed    


  136. DREGER P
    Comment to "The outcome of peripheral T-cell lymphoma patients failing first-line therapy".
    Haematologica. 2019;104:e178.
    PubMed    


  137. KUMAR A, Ying Z, Alperovich A, Dogan A, et al
    Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma.
    Haematologica. 2019;104:e163-e166.
    PubMed    


    March 2019
  138. BARRANCO GI, Fernandez S, Ona R, Gonzalez-Rincon J, et al
    Branched clonal evolution: nodal follicular lymphoma and primary diffuse large B-cell lymphoma of the central nervous system.
    Haematologica. 2019 Mar 19. pii: haematol.2018.214981.
    PubMed    


  139. CASADEI B, Broccoli A, Stefoni V, Pellegrini C, et al
    PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series.
    Haematologica. 2019 Mar 19. pii: haematol.2019.215962.
    PubMed    


  140. ROSSI D, Spina V, Bruscaggin A, Gaidano G, et al
    Liquid biopsy in lymphoma.
    Haematologica. 2019 Mar 7. pii: haematol.2018.206177.
    PubMed    


  141. GRANAI M, Ambrosio MR, Akarca A, Mundo L, et al
    Role of Epstein Barr virus in transformation of follicular lymphoma to diffuse large B-cell lymphoma: a case report and review of the literature.
    Haematologica. 2019 Mar 7. pii: haematol.2018.215053.
    PubMed    


  142. STEEN CB, Leich E, Myklebust JH, Lockmer S, et al
    A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.
    Haematologica. 2019 Mar 7. pii: haematol.2018.209080.
    PubMed    


    February 2019
  143. LOVISA F, Binatti A, Coppe A, Primerano S, et al
    A high definition picture of key genes and pathways mutated in pediatric follicular lymphoma.
    Haematologica. 2019 Feb 28. pii: haematol.2018.211631.
    PubMed    


  144. D'AGARO T, Zucchetto A, Vit F, Bittolo T, et al
    A B-cell receptor-related gene signature predicts response to ibrutinib treatmeant in mantle cell lymphoma cell lines.
    Haematologica. 2019 Feb 28. pii: haematol.2018.212811.
    PubMed    


  145. GRAETZ D, Crews KR, Azzato EM, Singh RK, et al
    Leukemic presentation of ALK+ Anaplastic Large Cell Lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib.
    Haematologica. 2019 Feb 28. pii: haematol.2018.215103.
    PubMed    


  146. HICKS SW, Tarantelli C, Wilhem A, Gaudio E, et al
    The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity than SAR3419 in CD19-positive lymphoma and leukemia models.
    Haematologica. 2019 Feb 7. pii: haematol.2018.211011.
    PubMed     Abstract available


  147. GONZALEZ-FARRE B, Ramis-Zaldivar JE, Salmeron-Villalobos J, Balague O, et al
    Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma genetically unrelated to Burkitt lymphoma.
    Haematologica. 2019 Feb 7. pii: haematol.2018.207928.
    PubMed     Abstract available


    January 2019
  148. TARANTELLI C, Zhang L, Curti E, Gaudio E, et al
    The BTK inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
    Haematologica. 2019 Jan 24. pii: haematol.2018.214759.
    PubMed    


  149. TOROSSIAN A, Broin N, Frentzel J, Daugrois C, et al
    Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.
    Haematologica. 2019 Jan 24. pii: haematol.2017.181966.
    PubMed     Abstract available


  150. QDAISAT A, Al Soud R, Wu CC, Rojas Hernandez CM, et al
    Poor performance of D-Dimer in excluding venous thromboembolism among patients with lymphoma and leukemia.
    Haematologica. 2019 Jan 10. pii: haematol.2018.211466.
    PubMed    


  151. TAKEUCHI M, Miyoshi H, Asano N, Yoshida N, et al
    Human leukocyte antigen class II expression is a good prognostic factor of adult T-cell leukemia/lymphoma.
    Haematologica. 2019 Jan 10. pii: haematol.2018.205567.
    PubMed     Abstract available


  152. SILVA A, Bassim S, Sarkozy C, Mottok A, et al
    Convergence of risk prediction models in follicular lymphoma.
    Haematologica. 2019 Jan 3. pii: haematol.2018.209031.
    PubMed    


  153. SASSE S, Reddemann K, Diepstra A, Borchmann S, et al
    Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment.
    Haematologica. 2019;104:e45-e46.
    PubMed    


  154. TAYLOR JG, Clear A, Calaminici M, Gribben JG, et al
    Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy.
    Haematologica. 2019;104:e42-e44.
    PubMed    


    December 2018
  155. QUALLS D, Abramson JS
    Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma.
    Haematologica. 2018 Dec 20. pii: haematol.2018.195834.
    PubMed     Abstract available


  156. BELHADJ M, Mansour D, Kaltenbach S, Deau-Fischer B, et al
    T-cell large granular lymphocyte leukemia transformation into aggressive T-cell lymphoma: a report of two cases with molecular characterization.
    Haematologica. 2018 Dec 20. pii: haematol.2018.205542.
    PubMed    


  157. PHILLIPS AA, Fields PA, Hermine O, Ramos JC, et al
    Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma.
    Haematologica. 2018 Dec 20. pii: haematol.2018.205096.
    PubMed     Abstract available


  158. SEYMOUR JF, Marcus R, Davies A, Gallop-Evans E, et al
    Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
    Haematologica. 2018 Dec 20. pii: haematol.2018.209015.
    PubMed     Abstract available


  159. ARESU L, Ferraresso S, Marconato L, Cascione L, et al
    New molecular and therapeutic insights into canine diffuse large B cell lymphoma elucidates the role of the dog as a model for human disease.
    Haematologica. 2018 Dec 13. pii: haematol.2018.207027.
    PubMed    


  160. DELAGE L, Manzoni D, Quinquenet C, Fontaine J, et al
    Molecular analysis of a CD19 negative diffuse large B cell lymphoma.
    Haematologica. 2018 Dec 13. pii: haematol.2018.203521.
    PubMed    


  161. UCHIDA A, Isobe Y, Asano J, Uemura Y, et al
    Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-protein-expression" lymphoma with MYC and BCL2 rearrangements.
    Haematologica. 2018 Dec 6. pii: haematol.2018.204958.
    PubMed     Abstract available


    November 2018
  162. RULE S, Dreyling M, Goy A, Hess G, et al
    Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow-up from a pooled analysis.
    Haematologica. 2018 Nov 15. pii: haematol.2018.205229.
    PubMed    


    October 2018
  163. HAGENBEEK A, Mooij H, Zijlstra J, Lugtenburg P, et al
    Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study.
    Haematologica. 2018 Oct 31. pii: haematol.2018.196899.
    PubMed    


  164. BURKHARD R, Keller I, Arambasic M, Juskevicius D, et al
    TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-kappaB mediated signaling in B-cells.
    Haematologica. 2018 Oct 31. pii: haematol.2018.201590.
    PubMed     Abstract available


  165. BERGMANN AK, Fataccioli V, Castellano G, Martin-Garcia N, et al
    DNA methylation profiling identifies candidate genes for the pathogenesis of hepatosplenic T-cell lymphoma.
    Haematologica. 2018 Oct 18. pii: haematol.2018.196196.
    PubMed    


  166. CASAGRANDE N, Borghese C, Visser L, Mongiat M, et al
    CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.
    Haematologica. 2018 Oct 11. pii: haematol.2018.196725.
    PubMed     Abstract available


  167. EVRARD SM, Pericart S, Grand D, Amara N, et al
    Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and /or BCL6 rearrangements.
    Haematologica. 2018 Oct 11. pii: haematol.2018.198572.
    PubMed    


    September 2018
  168. KUBOTA-TANAKA M, Osumi T, Miura S, Tsujimoto H, et al
    B-lymphoblastic lymphoma with the TCF3-PBX1 fusion gene.
    Haematologica. 2018 Sep 27. pii: haematol.2018.199885.
    PubMed    


  169. LEIVONEN SK, Pollari M, Bruck O, Pellinen T, et al
    T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.
    Haematologica. 2018 Sep 20. pii: haematol.2018.200105.
    PubMed     Abstract available


  170. OCHI Y, Hiramoto N, Yoshizato T, Ono Y, et al
    Clonally related diffuse large B-cell lymphoma and interdigitating dendritic cell sarcoma sharing MYC translocation.
    Haematologica. 2018 Sep 20. pii: haematol.2018.193490.
    PubMed    


  171. SCHUHMACHER B, Bein J, Rausch T, Benes V, et al
    JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte rich large B-cell lymphoma.
    Haematologica. 2018 Sep 13. pii: haematol.2018.203224.
    PubMed     Abstract available


  172. STRATI P, Fanale M, Oki Y, Turturro F, et al
    Rituximab with ABVD vs ABVD for advanced stage high-risk classical Hodgkin lymphoma: a randomized phase II study.
    Haematologica. 2018 Sep 6. pii: haematol.2018.199844.
    PubMed    


  173. EYRE TA, Walter HS, Iyengar S, Follows G, et al
    Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
    Haematologica. 2018 Sep 6. pii: haematol.2018.198812.
    PubMed    


    August 2018
  174. GRESSIN R, Daguindau N, Tempescul A, Moreau A, et al
    A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma.
    Haematologica. 2018 Aug 31. pii: haematol.2018.191429.
    PubMed     Abstract available


  175. KINOSHITA S, Ishida T, Ito A, Narita T, et al
    Cyclin-dependent kinase 9 as a potential specific molecular target in NK cell leukemia/lymphoma.
    Haematologica. 2018 Aug 3. pii: haematol.2018.191395.
    PubMed     Abstract available


  176. MENSAH AA, Cascione L, Gaudio E, Tarantelli C, et al
    Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.
    Haematologica. 2018 Aug 3. pii: haematol.2018.191684.
    PubMed     Abstract available


  177. SASSE S, Reddemann K, Diepstra A, Oschlies I, et al
    Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.
    Haematologica. 2018 Aug 3. pii: haematol.2018.196279.
    PubMed    


  178. DE SMEDT R, Peirs S, Morscio J, Matthijssens F, et al
    Preclinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.
    Haematologica. 2018 Aug 3. pii: haematol.2018.199257.
    PubMed    


  179. MELANI C, Roschewski M, Wilson WH
    End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al.
    Haematologica. 2018;103:e382.
    PubMed    


  180. ADAMS HJA, Kwee TC
    Unproven value of end-of-treatment and serial follow-up FDG-PET in primary mediastinal B-cell lymphoma.
    Haematologica. 2018;103:e380-e381.
    PubMed    


    July 2018
  181. POLLARI M, Bruck O, Pellinen T, Vahamurto P, et al
    PD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict survival in primary testicular lymphoma.
    Haematologica. 2018 Jul 19. pii: haematol.2018.197194.
    PubMed     Abstract available


  182. DE CHARETTE M, Houot R
    Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.
    Haematologica. 2018 Jul 13. pii: haematol.2017.184192.
    PubMed     Abstract available


  183. VILLA D, Sehn LH, Aquino-Parsons C, Tonseth P, et al
    Interim PET-directed therapy in limited stage Hodgkin lymphoma initially treated with ABVD.
    Haematologica. 2018 Jul 12. pii: haematol.2018.196782.
    PubMed    


  184. ARAF S, Wang J, Ashton-Key M, Korfi K, et al
    Transmission of diffuse large B cell lymphoma by an allogeneic stem-cell transplant.
    Haematologica. 2018 Jul 5. pii: haematol.2018.196907.
    PubMed    


    June 2018
  185. AMBROSIO MR, Lazzi S, Lo Bello G, Santi R, et al
    MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.
    Haematologica. 2018 Jun 28. pii: haematol.2018.195958.
    PubMed    


  186. RECASENS-ZORZO C, Cardesa-Salzmann T, Petazzi P, Ros-Blanco L, et al
    Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.
    Haematologica. 2018 Jun 28. pii: haematol.2017.180505.
    PubMed     Abstract available


  187. EPSTEIN MM, Rosner B, Breen EC, Batista JL, et al
    Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies.
    Haematologica. 2018 Jun 21. pii: haematol.2017.183236.
    PubMed     Abstract available


  188. MCPHAIL ED, Maurer MJ, Macon WR, Feldman AL, et al
    Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.
    Haematologica. 2018 Jun 14. pii: haematol.2018.190157.
    PubMed     Abstract available


  189. PEREZ-SALVIA M, Aldaba E, Vara Y, Fabre M, et al
    In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma.
    Haematologica. 2018 Jun 7. pii: haematol.2018.189241.
    PubMed    


    May 2018
  190. ESKELUND CW, Albertsson-Lindblad A, Kolstad A, Laurell A, et al
    Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.
    Haematologica. 2018 May 24. pii: haematol.2018.194399.
    PubMed    


  191. STORTI S, Spina M, Pesce EA, Salvi F, et al
    Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.
    Haematologica. 2018 May 10. pii: haematol.2017.186569.
    PubMed     Abstract available


  192. TRNENY M, Verhoef G, Dyer MJ, Yehuda DB, et al
    A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.
    Haematologica. 2018 May 10. pii: haematol.2017.168401.
    PubMed     Abstract available


  193. MELANI C, Advani R, Roschewski M, Walters KM, et al
    End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted-EPOCH-R: A paradigm shift in clinical decision making.
    Haematologica. 2018 May 10. pii: haematol.2018.192492.
    PubMed     Abstract available


    April 2018
  194. STRATI P, Chihara D, Oki Y, Fayad LE, et al
    A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
    Haematologica. 2018 Apr 5. pii: haematol.2018.187617.
    PubMed    


  195. KUPPERS R
    CD83 in Hodgkin lymphoma.
    Haematologica. 2018;103:561-562.
    PubMed    


    March 2018
  196. BELLEI M, Foss FM, Shustov AR, Horwitz SM, et al
    The outcome of peripheral T-cell lymphoma patients failing first line therapy: a report from the prospective, international T-Cell project.
    Haematologica. 2018 Mar 29. pii: haematol.2017.186577.
    PubMed     Abstract available


  197. HORN H, Kohler C, Witzig R, Kreuz M, et al
    Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2.
    Haematologica. 2018 Mar 22. pii: haematol.2017.181024.
    PubMed     Abstract available


  198. ALIG S, Jurinovic V, Pastore A, Bararia D, et al
    Impact of age on genetics and treatment efficacy in follicular lymphoma.
    Haematologica. 2018 Mar 15. pii: haematol.2018.187773.
    PubMed    


  199. MAFFINI E, Anderson LD Jr., Sandmaier BM, Green DJ, et al
    Nonmyeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenstrom macroglobulinemia: Evidence for a graft-versus-lymphoma effect.
    Haematologica. 2018 Mar 15. pii: haematol.2017.184176.
    PubMed    


  200. NIJLAND ML, Koens L, Pals ST, Berge IJMT, et al
    Clinicopathological characteristics of T-cell non-Hodgkin lymphoma arising in patients with immunodeficiencies: a single-center case series of 25 patients and a review of the literature.
    Haematologica. 2018;103:486-496.
    PubMed     Abstract available


  201. LEMONNIER F, Poullot E, Dupuy A, Couronne L, et al
    Loss of 5-hydroxymethylcytosine is a frequent event in peripheral T-cell lymphomas.
    Haematologica. 2018;103:e115-e118.
    PubMed    


  202. WANG X, Chen Z, Mishra AK, Silva A, et al
    Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition.
    Haematologica. 2018;103:466-476.
    PubMed     Abstract available


    February 2018
  203. BOMBEN R, Ferrero S, D'Agaro T, Dal Bo M, et al
    A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial.
    Haematologica. 2018 Feb 22. pii: haematol.2017.184325.
    PubMed     Abstract available


  204. BIRSEN R, Willems L, Pallud J, Blanc E, et al
    Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.
    Haematologica. 2018 Feb 22. pii: haematol.2017.185843.
    PubMed    


  205. RIMSZA LM, Li H, Braziel RM, Spier CM, et al
    Impact of histologic grading on survival in the SWOG S0016 follicular lymphoma cohort.
    Haematologica. 2018 Feb 22. pii: haematol.2017.175059.
    PubMed     Abstract available


  206. SUEHARA Y, Sakata-Yanagimoto M, Hattori K, Nanmoku T, et al
    Liquid biopsy for the identification of intravascular large B-cell lymphoma.
    Haematologica. 2018 Feb 22. pii: haematol.2017.178830.
    PubMed     Abstract available


  207. ARVIDSSON G, Henriksson J, Sander B, Wright AP, et al
    Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients
    Haematologica. 2018 Feb 15. pii: haematol.2017.182048.
    PubMed     Abstract available


  208. SCHOMMERS P, Gillor D, Hentrich M, Wyen C, et al
    Incidence and risk factors for relapses in HIV-associated non-Hodgkin-lymphoma as observed in the German HIV-related lymphoma cohort study.
    Haematologica. 2018 Feb 8. pii: haematol.2017.180893.
    PubMed     Abstract available


  209. SHALABI H, Kraft IL, Wang HW, Yuan CM, et al
    Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma.
    Haematologica. 2018 Feb 1. pii: haematol.2017.183459.
    PubMed     Abstract available


    January 2018
  210. FUJI S, Utsunomiya A, Inoue Y, Miyagi T, et al
    Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation.
    Haematologica. 2018 Jan 25. pii: haematol.2017.184564.
    PubMed    


  211. LI Z, Ju X, Lee K, Clarke C, et al
    CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.
    Haematologica. 2018 Jan 19. pii: haematol.2017.178384.
    PubMed     Abstract available


  212. VAN DEN NESTE E, Andre M, Gastinne T, Stamatoullas A, et al
    Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.
    Haematologica. 2018 Jan 19. pii: haematol.2017.180554.
    PubMed     Abstract available


  213. JI MM, Huang YH, Huang JY, Wang ZF, et al
    Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
    Haematologica. 2018 Jan 5. pii: haematol.2017.182444.
    PubMed     Abstract available


    December 2017
  214. KNORR F, Damm-Welk C, Ruf S, Singh VK, et al
    Blood cytokine concentrations of pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma patients.
    Haematologica. 2017 Dec 14. pii: haematol.2017.177972.
    PubMed     Abstract available


  215. BOBILLO S, Abrisqueta P, Carpio C, Raheja P, et al
    Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.
    Haematologica. 2017 Dec 14. pii: haematol.2017.181636.
    PubMed    


  216. AUNER HW, Iacobelli S, Sbianchi G, Knol-Bout C, et al
    Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.
    Haematologica. 2017 Dec 7. pii: haematol.2017.181339.
    PubMed     Abstract available


    November 2017
  217. TRACY SI, Habermann TM, Feldman AL, Maurer MJ, et al
    Outcomes among US patients with diffuse large B cell lymphoma are independent of tumor Epstein Barr virus positivity or immunosuppression.
    Haematologica. 2017 Nov 23. pii: haematol.2017.176511.
    PubMed     Abstract available


  218. COUTRE S, Tedeschi A, Robak T, Barr PM, et al
    Survival adjusting for crossover: phase 3 study of ibrutinib vs chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Haematologica. 2017 Nov 23. pii: haematol.2017.175380.
    PubMed    


  219. BOSCH M, Akhter A, Chen BE, Mansoor A, et al
    A bio-clinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.
    Haematologica. 2017 Nov 2. pii: haematol.2017.179309.
    PubMed     Abstract available


  220. NG SB, Chung TH, Kato S, Nakamura S, et al
    EBV-associated primary nodal T/NK-cell lymphoma shows distinct molecular signature and copy number changes.
    Haematologica. 2017 Nov 2. pii: haematol.2017.180430.
    PubMed     Abstract available


    October 2017
  221. RUDELIUS M, Rosenfeldt MT, Leich E, Rauert-Wunderlich H, et al
    Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
    Haematologica. 2017 Oct 27. pii: haematol.2017.177162.
    PubMed     Abstract available


  222. LANDMANN E, Burkhardt B, Zimmermann M, Meyer U, et al
    Results and conclusions of the European Intergroup EURO-LB02 Trial in children and adolescents with lymphoblastic lymphoma.
    Haematologica. 2017 Oct 5. pii: haematol.2015.139162.
    PubMed     Abstract available


    September 2017
  223. YOUNES A, Salles G, Martinelli G, Bociek RG, et al
    Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed and refractory non-Hodgkin lymphoma.
    Haematologica. 2017 Sep 29. pii: haematol.2017.169656.
    PubMed     Abstract available


  224. LUGTENBURG P, Avivi I, Berenschot H, Ilhan O, et al
    Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.
    Haematologica. 2017 Sep 21. pii: haematol.2017.173583.
    PubMed     Abstract available


  225. EICHENAUER DA, Becker I, Monsef I, Chadwick N, et al
    Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials.
    Haematologica. 2017 Sep 14. pii: haematol.2017.167478.
    PubMed     Abstract available


    August 2017
  226. OKI Y, Kelly KR, Flinn I, Patel MR, et al
    CUDC-907 in relapsed/refractory diffuse Large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase 1 trial.
    Haematologica. 2017 Aug 31. pii: haematol.2017.172882.
    PubMed     Abstract available


  227. VIDAL-CRESPO A, Rodriguez V, Matas-Cespedes A, Lee E, et al
    The BTK inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on the NF-kappaB mutational status.
    Haematologica. 2017 Aug 24. pii: haematol.2017.168930.
    PubMed    


  228. BROCCOLI A, Pellegrini C, Di Rocco A, Puccini B, et al
    Italian real life experience with brentuximab vedotin: results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma.
    Haematologica. 2017 Aug 3. pii: haematol.2017.171355.
    PubMed     Abstract available


    July 2017
  229. MONDELAERS V, Suciu S, De Moerloose B, Ferster A, et al
    Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
    Haematologica. 2017 Jul 27. pii: haematol.2017.165845.
    PubMed     Abstract available


  230. JALLADES L, Baseggio L, Sujobert P, Huet S, et al
    Exome sequencing identifies recurrent BCOR gene alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma.
    Haematologica. 2017 Jul 27. pii: haematol.2016.160192.
    PubMed     Abstract available


  231. JAIS JP, Molina TJ, Ruminy P, Gentien D, et al
    Reliable subtype classification of diffuse large B-Cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay.
    Haematologica. 2017 Jul 4. pii: haematol.2017.166827.
    PubMed    


  232. FERRERO S, Dreyling M
    Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?
    Haematologica. 2017;102:1133-1136.
    PubMed    


    June 2017
  233. VAN DE KROGT JA, Vanden Bempt M, Finalet Ferreiro J, Mentens N, et al
    ALK-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
    Haematologica. 2017 Jun 28. pii: haematol.2016.146571.
    PubMed     Abstract available


  234. EHRENTRAUT S, Nagel S, Pommerenke C, Dirks WG, et al
    Peripheral T-cell lymphoma cell line T8ML-1 highlights conspicuous targeting of PVRL2 by t(14;19)(q11.2;q13.3).
    Haematologica. 2017 Jun 28. pii: haematol.2017.168203.
    PubMed    


  235. BRON D, Aurer I, Andre MPE, Bonnet C, et al
    Unmet needs in the scientific approach to older patients with lymphoma.
    Haematologica. 2017;102:972-975.
    PubMed    


    May 2017
  236. CAMPOS-MARTIN Y, Martinez N, Martinez-Lopez A, Cereceda L, et al
    Clinical and diagnostic relevance of NOTCH2 and KLF2 mutations in splenic marginal zone lymphoma.
    Haematologica. 2017 May 18. pii: haematol.2016.161711.
    PubMed    


  237. DAVID A, Arnaud N, Fradet M, Lascaux H, et al
    c-Myc dysregulation is a co-transforming event for nuclear factor-kappaB activated B cells.
    Haematologica. 2017;102:883-894.
    PubMed     Abstract available


    April 2017
  238. STEVENS WBC, Mendeville M, Redd R, Clear AJ, et al
    Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: A study by the Lunenburg Lymphoma Biomarker Consortium.
    Haematologica. 2017 Apr 14. pii: haematol.2017.165415.
    PubMed     Abstract available


  239. NOBLE RA, Bell N, Blair H, Sikka A, et al
    Inhibition of monocarboxylate transporter 1 by AZD3965 as a novel therapeutic approach for the treatment of diffuse large B-cell lymphoma and Burkitt lymphoma.
    Haematologica. 2017 Apr 6. pii: haematol.2016.163030.
    PubMed     Abstract available


  240. BI C, Zhang X, Lu T, Zhang X, et al
    Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas.
    Haematologica. 2017;102:755-764.
    PubMed     Abstract available


    March 2017
  241. FUJI S, Yamaguchi T, Inoue Y, Utsunomiya A, et al
    Development of a modified prognostic index of patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: a possible risk-adapted management strategies including allogeneic transplantation.
    Haematologica. 2017 Mar 24. pii: haematol.2017.164996.
    PubMed     Abstract available


  242. DENG AL, Kim YR, Lichtenstein EA, O'Connor OA, et al
    Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B cell lymphoma leg type with mutant MYD88 and wildtype CD79.
    Haematologica. 2017 Mar 24. pii: haematol.2016.161893.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: